PYY (Human/Mouse/Rat) ELISA Kit

Name: PYY (Human/Mouse/Rat) ELISA Kit
SKU: DEIA4124
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

cell lysates, culture supernatant, plasma, serum

Species Reactivity

Human; Mouse; Rat

Detection Method

Competitive ELISA

Intended Use

This kit is an in vitro quantitative assay for detecting PYY peptide based on the principle of Competitive Enzyme Immunoassay.

Contents of Kit

1. PYY Microplate
2. Wash Buffer Concentrate (20X)
3. Standard PYY Peptide
4. Anti-PYY polyclonal antibody
5. Assay Diluent A
6. Assay Diluent B
7. Biotinylated PYY peptide
8. HRP-Streptavidin concentrate
9. Positive control
10. TMB One-Step Substrate Reagent
11. Stop Solution
12. Sealing tape

Storage

Standard, Biotinylated PYY peptide, and Positive Control should be stored at -20°C or -80°C (recommended at -80°C) after arrival. Avoid multiple freeze-thaws.
The remaining kit components may be stored at -20°C.
Opened Microplate Wells and antibody (Item N) may be stored for up to 1 month at 2-8°C. Return unused wells to the pouch containing desiccant pack and reseal along entire edge.
If stored in this manner, Abnova warranties this kit for 6 months from the date of shipment.

Precision

Intra-assay: CV<10%
Inter-assay: CV<15%

Detection Range

0.1-1000 pg/mL

Sensitivity

2.84 pg/mL

Citations

Have you cited DEIA4124 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Ghrelin and Peptide YY Change During Puberty: Relationships With Adolescent Growth, Development, and Obesity

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Authors: Cheng, Hoi Lun; Sainsbury, Amanda; Garden, Frances; Sritharan, Myuran; Paxton, Karen; Luscombe, Georgina; Hawke, Catherine; Steinbeck, Katharine

Abstract

Context: Pubertal adolescents show strong appetites. How this is mediated is unclear, but ghrelin and peptide YY (PYY) play potentially important roles. Objective: To measure ghrelin and PYY change in relation to pubertal growth. Design: Three-year prospective cohort study. Setting: Australian regional community. Participants: Eighty healthy adolescents (26 girls; 54 boys) recruited at 10 to 13 years. Main Outcome Measures: Fasting circulating total ghrelin, total PYY, IGF-1, insulin, leptin (via radioimmunoassay), estradiol and testosterone (via mass spectrometry), anthropometry, and body composition (via bioelectrical impedance). Results: Adolescents exhibited normal developmental change. Mixed models revealed positive associations for ghrelin to age2 (both sexes: P < 0.05), indicating a U-shaped trend over time. Ghrelin was also inversely associated with IGF-1 (both sexes: P < 0.05), leptin in girls (P < 0.01), and insulin in boys (P < 0.05) and negatively correlated with annual height and weight velocity (both sexes: P <= 0.01). PYY showed no age-related change in either sex. Neither ghrelin nor PYY were associated with Tanner stage. Weight subgroup analyses showed significant ghrelin associations with age2 in healthy-weight but not overweight and obese adolescents (7 girls; 18 boys). Conclusions: Adolescents showed a U-shaped change in ghrelin corresponding to physical and biochemical markers of growth, and no change in PYY. The overweight and obesity subgroup exhibited an apparent loss of the U-shaped ghrelin trend, but this finding may be attributed to greater maturity and its clinical significance is unclear. Further research on weight-related ghrelin and PYY trends at puberty is needed to understand how these peptides influence growth and longterm metabolic risk.

Endoscopic Bariatric and Metabolic Therapies: Surgical Analogues and Mechanisms of Action

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

Authors: Jirapinyo, Pichamol; Thompson, Christopher C.

Abstract

Obesity is a worsening pandemic with numerous related comorbid illnesses. Conservative management including lifestyle modification and medications have limited efficacy. In contradistinction, bariatric surgery is effective, however, with substantial cost and non-negligible morbidity and mortality. As such, a small percentage of eligible patients undergo surgery. Over the past decade, endoscopic bariatric and metabolic therapies have been introduced as a less invasive option for the treatment of obesity and its related comorbid illnesses. This article reviews major endoscopic bariatric and metabolic therapies, their surgical analogues, and proposed mechanisms of action. Clinical trial data for each device also are discussed.